Liver/Biliary
  • What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • CMGH now Searchable in PubMed!

CMGH now Searchable in PubMed!

Cellular and Molecular Gastroenterology and Hepatology (CMGH), published by the American Gastroenterological Association, has been accepted for indexing in PubMed Central, which will make all CMGH articles, starting with Volume 1, Issue 1, searchable as full text in PubMed over the next several weeks. In an editorial written for the September

Read more
  • A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

Using 2 powerful high-throughput in vivo screening tools, researchers identified and validated 27 genes as suppressors of hepatocellular carcinoma (HCC), reported in the August issue of Gastroenterology. Their findings support the role of Ras signaling in development of HCC and provide new therapeutic targets. Sorafenib is the only treatment for patients

Read more
  • Do Nonselective Beta Blockers Increase Mortality in Patients With Cirrhosis and Ascites?

Do Nonselective Beta Blockers Increase Mortality in Patients With Cirrhosis and Ascites?

Nonselective beta blockers (NSBBs) do not significantly increase the risk of death in patients with cirrhosis and ascites or refractory ascites, researchers report in the August issue of Clinical Gastroenterology and Hepatology. The findings from this meta-analysis do not support the position that NSBBs be routinely withheld from patients with

Read more
  • Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more
  • What is the Most Effective Method for Treating Unresectable Malignant Distal Biliary Obstruction?

What is the Most Effective Method for Treating Unresectable Malignant Distal Biliary Obstruction?

Endoscopic ultrasound-guided biliary drainage (EUS-BD) and percutaneous transhepatic biliary drainage (PTBD) are equally effective in treating patients with unresectable malignant distal biliary obstruction and inaccessible papilla, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, EUS-BD produced fewer procedure-related adverse events and unscheduled re-interventions. PTBD has been

Read more
  • Gastroenterology Special Isssue on Alcoholic vs Non-Alcoholic Fatty Liver Disease

Gastroenterology Special Isssue on Alcoholic vs Non-Alcoholic Fatty Liver Disease

A special issue of Gastroenterology is devoted to comparing alcoholic vs nonalcoholic fatty liver disease. In an introduction to the issue, Arun Sanyal et al write that alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have much in common, including histologic features and activation of pathways involved in their pathogenesis. They also have some

Read more
  • How Could Variants in TM6SF2 Affect Risk for NAFLD?

How Could Variants in TM6SF2 Affect Risk for NAFLD?

The human transmembrane 6 superfamily member 2 (TM6SF2) protein regulates cholesterol metabolism in mice, researchers report in the May issue of Gastroenterology. These findings provide insight into the how a variant of TM6SF2 (encoding the amino acid change E167K) reduces total cholesterol and low-density lipoprotein cholesterol (LDL-c) levels in humans, and

Read more
  • Do NSAIDs Prevent PEP?

Do NSAIDs Prevent PEP?

Rectal indomethacin does not prevent pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP), researchers report from a randomized controlled study published in the April issue of Gastroenterology. These findings contradict more than a decade of evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) decrease the risk of post-ERCP pancreatitis (PEP). Acute pancreatitis is the

Read more
  • Alcohol Consumption and Fatty Liver—A Double Whammy for Liver Cancer Risk

Alcohol Consumption and Fatty Liver—A Double Whammy for Liver Cancer Risk

High to intermediate levels of ethanol consumption increase the risk for liver cancer in patients with fatty liver disease, researchers report in the April issue of Clinical Gastroenterology and Hepatology. Nonalcoholic fatty liver disease is a common cause of chronic liver disease associated with obesity, dyslipidemia, pituitary dysfunction, hypertension, sleep

Read more